A novel approach to antibody development has received the backing of the global medical charity, the Wellcome Trust. Kymab Ltd of Cambridge UK has received £20 million in a Series A round to develop its technology platform. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News Regenerative Medicine
